{
    "clinical_study": {
        "@rank": "70355", 
        "acronym": "NEXIRI 2", 
        "arm_group": [
            {
                "arm_group_label": "Irinotecan monotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Intravenous infusion irinotecan 180 mg/m2 over 90 minutes (D1=D15) with cross over to irinotecan and sorafenib combination at progression."
            }, 
            {
                "arm_group_label": "Sorafenib monotherapy", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral sorafenib 400 mg twice daily (total dose 800 mg/day) with cross over to irinotecan and sorafenib combination at progression"
            }, 
            {
                "arm_group_label": "Sorafenib and irinotecan combination", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous infusion irinotecan 120 mg/m2 over 90 minutes (D1=D15) at Cycle 1, 150 mg/m\u00b2 at C2 if no diarrhea > grade 1 and no other toxicity > grade 2, and 180 mg/m\u00b2 at C3 in the same conditions\nOral sorafenib 400 mg twice daily (total dose 800 mg/day) from C1. 1 cycle = 15 days and 1 course = 4 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this multicenter randomized phase II trial is to determine the efficacy of\n      sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib\n      monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure\n      of all active drugs known to be effective."
        }, 
        "brief_title": "A Trial to Assess Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors", 
        "completion_date": {
            "#text": "September 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female \u2265 18 years old\n\n          -  Histologically confirmed diagnosis of colorectal cancer\n\n          -  Asymptomatic or resected primary tumor\n\n          -  Metastatic colorectal cancer patient not eligible for curative surgery\n\n          -  At least one target lesion:\n\n               -  Unidimensionally measurable on cross-sectional imaging\n\n               -  In an area not previously irradiated\n\n          -  Disease progression after failure of active drugs (5-Fu or 5-Fu prodrugs, irinotecan,\n             oxaliplatin, bevacizumab)\n\n          -  Patients with bone metastases are eligible if they have other measurable lesions\n\n          -  WHO performance status \u2264 2\n\n          -  Confirmation of KRAS mutation in codons 12 or 13 in the primary tumor or metastases\n\n          -  Total bilirubin \u2264 1.5 ULN, ALT or AST \u2264 2.5 ULN (or < 5 in case of liver impairment)\n\n          -  Haemoglobin \u2265 10 g/dL, neutrophils \u2265 1,500/mm3, platelets \u2265 100,000/mm3\n\n          -  Serum creatinine \u2264 1.5 ULN\n\n          -  Negative pregnancy test in women of childbearing potential\n\n          -  Use of an effective contraceptive method during the whole treatment and up to 3\n             months after the completion of treatment in males and females\n\n          -  Life expectancy of at least 3 months\n\n          -  Informed consent signed prior any study specific procedures\n\n          -  Tumor evaluation should be performed within 3 weeks prior to starting  treatment\n\n        Exclusion Criteria:\n\n          -  History of Gilbert's syndrome\n\n          -  Symptomatic brain metastases or carcinomatous meningitis\n\n          -  Bone-only metastases\n\n          -  History or presence of other cancers within the past 5 years (except curatively\n             treated non-melanoma skin cancer and in situ cervical cancer)\n\n          -  Prior surgery or radiotherapy within 4 weeks before entering the study\n\n          -  Cardiac arrhythmia requiring treatment (except for beta-blockers and digoxin),\n             unstable cardiac disease, myocardial infarction within the previous 6 months, > grade\n              II NYHA heart failure, uncontrolled hypertension\n\n          -  Kalemia lower than normal serum potassium value\n\n          -  From ECG, QTc interval > 470 ms\n\n          -  History of acute or chronic pancreatitis\n\n          -  History of epileptic seizures requiring long-term anticonvulsant therapy\n\n          -  History of organ transplantation with use of immunosuppression therapy\n\n          -  Severe bacterial or fungal infection (Grade > 2 NCI-CTCAE v.4.0)\n\n          -  Known HIV infection\n\n          -  Long-term use of CYP 3A4 enzyme-inducing agents such as rifampicin, St. John's Wort\n             (hypericum perforatum), phenytoin, carbamazepine, phenobarbital, dexamethasone, and\n             ketoconazole\n\n          -  Pregnant or breastfeeding women\n\n          -  Bowel malabsorption or extended bowel resection that could affect the absorption of\n             sorafenib, occlusive syndrome, inability to take oral medications\n\n          -  Inflammatory bowel disease with chronic diarrhea (NCI-CTCAE v.4.0)\n\n          -  Participation in another clinical trial 30 days prior to study entry\n\n          -  Concurrent treatment with any other investigational product or anticancer therapy\n             (except for irinotecan or sorafenib)\n\n          -  Psychological, social, geographical disorders or any other condition that would\n             preclude study compliance (treatment administration and study follow-up)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "160", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715441", 
            "org_study_id": "NEXIRI2", 
            "secondary_id": "2012-000644-94"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sorafenib and irinotecan combination", 
                "intervention_name": "Sorafenib and irinotecan combination", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Sorafenib monotherapy", 
                "intervention_name": "Sorafenib monotherapy", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Irinotecan monotherapy", 
                "intervention_name": "Irinotecan monotherapy", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Sorafenib"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Metastatic colorectal cancer patients", 
            "KRAS mutation", 
            "Sorafenib"
        ], 
        "lastchanged_date": "February 4, 2014", 
        "location": [
            {
                "contact": {
                    "email": "Thomas.aparicio@avc.aphp.fr", 
                    "last_name": "Thomas APARICIO, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Bobigny", 
                        "country": "France", 
                        "zip": "93009"
                    }, 
                    "name": "H\u00f4pital AVICENNE"
                }, 
                "investigator": {
                    "last_name": "Thomas APARICIO, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Marie-Pierre GALAIS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Caen", 
                        "country": "France", 
                        "zip": "14076"
                    }, 
                    "name": "Centre Fran\u00e7ois Baclesse"
                }, 
                "investigator": {
                    "last_name": "Marie-Pierre GALAIS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "a-adenis@o-lambret.fr", 
                    "last_name": "Antoine ADENIS, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lille", 
                        "country": "France", 
                        "zip": "59020"
                    }, 
                    "name": "Centre Oscar Lambret"
                }, 
                "investigator": {
                    "last_name": "Antoine ADENIS, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fran\u00e7oise DESSEIGNE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Lyon", 
                        "country": "France", 
                        "zip": "69373"
                    }, 
                    "name": "Centre L\u00e9on B\u00e9rard"
                }, 
                "investigator": {
                    "last_name": "Fran\u00e7oise DESSEIGNE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jean-fran\u00e7ois.seitz@ap-hm.fr", 
                    "last_name": "Jean-Fran\u00e7ois SEITZ, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Marseille", 
                        "country": "France", 
                        "zip": "13365"
                    }, 
                    "name": "H\u00f4pital LA TIMONE"
                }, 
                "investigator": {
                    "last_name": "Jean-Fran\u00e7ois SEITZ, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Emmanuelle SAMALIN, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Montpellier", 
                        "country": "France", 
                        "zip": "34298"
                    }, 
                    "name": "CRLC Val d'Aurelle-Paul Lamarque"
                }, 
                "investigator": {
                    "last_name": "Emmanuelle SAMALIN, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Obouche@chu-reims.fr", 
                    "last_name": "Olivier BOUCHE, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Reims", 
                        "country": "France", 
                        "zip": "51092"
                    }, 
                    "name": "C.H.U. de REIMS"
                }, 
                "investigator": {
                    "last_name": "Olivier BOUCHE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Frederic.Di-Fiore@chu-rouen.fr", 
                    "last_name": "Fr\u00e9d\u00e9ric Di FIORE, MD", 
                    "phone": "33 2.32.88.81.01"
                }, 
                "facility": {
                    "address": {
                        "city": "Rouen", 
                        "country": "France", 
                        "zip": "76038"
                    }, 
                    "name": "CHU Charles Nicolle"
                }, 
                "investigator": {
                    "last_name": "Fr\u00e9d\u00e9ric Di FIORE, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Jaafa.bennouna@ico.unicancer.fr", 
                    "last_name": "Jaafa BENNOUNA, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "St. Herblain", 
                        "country": "France", 
                        "zip": "44805"
                    }, 
                    "name": "Institut de Canc\u00e9rologie de l'Ouest - Ren\u00e9 Gauducheau"
                }, 
                "investigator": {
                    "last_name": "Jaafa BENNOUNA, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective", 
        "other_outcome": {
            "measure": "Cmax and Tmax of sorafenib and irinotecan", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 months"
        }, 
        "overall_contact": {
            "email": "Jean-Pierre.Bleuse@montpellier.unicancer.fr", 
            "last_name": "Jean-Pierre Bleuse, MD", 
            "phone": "33 4 67 61 23 44"
        }, 
        "overall_official": [
            {
                "affiliation": "CRLC Val d'Aurelle-Paul Lamarque", 
                "last_name": "Emmanuelle SAMALIN, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CRLC Val d'Aurelle", 
                "last_name": "Marc YCHOU, MD,", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Afssaps - Agence fran\u00e7aise de s\u00e9curit\u00e9 sanitaire des produits de sant\u00e9 (Saint-Denis)", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the non-progression rate at 2 months according to RECIST criteria (Version 1.1)", 
            "measure": "Non-progression rate", 
            "safety_issue": "No", 
            "time_frame": "At 2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715441"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "According to RECIST criteria (Version 1.1)", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "At 2 months"
            }, 
            {
                "description": "According to NCI CTC V4.0", 
                "measure": "Treatment-related toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "At 6 months"
            }, 
            {
                "description": "Overall survival is defined as the time from the date of inclusion to the date of death from any cause.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "At 6 months"
            }, 
            {
                "description": "Using the EORTC QLQ-C30 questionnaire", 
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "Progression Free Survival is defined as the time from the date of inclusion to first documentation of objective tumor progression or to death due to progression.", 
                "measure": "Progression Free Survival", 
                "safety_issue": "No", 
                "time_frame": "At 6 months"
            }, 
            {
                "description": "According to RECIST criteria (Version 1.1)", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "At 2 months"
            }
        ], 
        "source": "Centre Val d'Aurelle - Paul Lamarque", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Centre Val d'Aurelle - Paul Lamarque", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}